Application Notes:
Anti-ganglioside GD1b (anti-GD1b) is very useful in the identification of disialoganglioside GD1b and in immunotargeting
cells expressing disialoganglioside GD1b. Several gangliosides have been found to have elevated expressions in tumor cells.
Many therapeutic treatments of tumor cells are being investigated using antibodies to target cells that express these elevated
levels of gangliosides. GD1b may be a target molecule for autoantibodies in some patients with acute sensory ataxic
neuropathy.3 Anti-GD1b has been found in some patients with Guillain–Barré syndrome (a disorder affecting the peripheral
nervous system) and may contribute to the pathogenesis of sensory disturbance and demyelination.4
References:
1. H. Yoshino, et al. “Fucosyl-GM1 in Human Sensory Nervous Tissue Is a Target Antigen in Patients with Autoimmune Neuropathies” Journal of
Neurochemistty, Vol. 61 pp. 658, 1993
2. S. Kusunoki, et al. “Neuropathy and IgM paraproteinemia: Differential binding of IgM M-proteins to peripheral nerve glycolipids” Neurology, Vol. 37 pp.
1795, 1987
3. C. Pan et al. “Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody” Neurology, vol. 57(7) pp. 1316-1318, 2001
4. F. Notturno MD, C. Caporale MD, A. Uncini MD “Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt
recovery” Muscle & Nerve, Vol. 37(2) pg. 265–268, 2008